Biology, Pathology & Genetic Profiling
At a Glance
For perihilar cholangiocarcinoma (pCCA), achieving an R0 (negative) margin during surgery is crucial for long-term survival. Tumors should also undergo NGS genetic testing to check for mutations and immunotherapy markers like MSI-High, which help guide targeted treatment plans.
Your cancer’s biology—where it started, how it is removed, and its “genetic instructions”—determines the most effective strategy for your care.
The Hidden Origin: Peribiliary Glands
Researchers believe that pCCA often begins in the peribiliary glands—tiny glands tucked inside the walls of the larger bile ducts [1]. Because of this, the cancer often creeps along and through the layers of the duct walls rather than growing as a single visible lump [1]. This unique biology requires highly precise surgical removal.
The “Margin” of Success: R0 vs. R1
If you have surgery, the most important term in your pathology report is your margin status. The margin is the edge of the tissue the surgeon removed.
- R0 Margin (Negative): The pathologist saw no cancer cells at the edge of the tissue. Achieving an R0 margin is a critical goal and is the strongest predictor for long-term survival [2][3].
- R1 Margin (Positive): Cancer cells were found at the very edge of the removed tissue, suggesting microscopic cells remain in the body [3]. Adjuvant therapies (like chemotherapy) are especially important if you have an R1 margin [4].
Reading the Genetic Blueprint (NGS)
Today, a biopsy is often sent for Next-Generation Sequencing (NGS) to “read” the tumor’s DNA [5]. Note: NGS testing can take several weeks to return results.
Targeted Therapy and Prognosis Markers
While targetable mutations (like FGFR2 or IDH1) are common in cancers inside the liver (intrahepatic), they are much rarer in perihilar tumors. However, testing is still standard to look for other markers:
- KRAS: A common mutation in pCCA. While there are currently limited drugs targeting KRAS directly in pCCA, its presence helps doctors understand the tumor’s biology, as it is an independent predictor of a more aggressive disease course [6].
- Other Markers: Doctors occasionally find targetable mutations like BRAF or HER2 (ERBB2), which may qualify you for specialized treatments or clinical trials [5].
Immunotherapy Markers: MSI-High
NGS also checks your tumor’s Microsatellite Instability (MSI) status and Tumor Mutational Burden (TMB). If a tumor is MSI-High or has a high TMB, it means its DNA repair system is broken [7]. These specific patients can often have excellent responses to immunotherapy (like pembrolizumab), which helps your own immune system recognize and attack the cancer [7][8].
Common questions in this guide
What does an R0 margin mean after pCCA surgery?
Why do I need Next-Generation Sequencing (NGS) for my tumor?
What does it mean if my tumor is MSI-High?
How long do genetic testing results take for pCCA?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Did my pathology report show R0 margins? If R1, what is the plan?
- 2.Has my tumor tissue been sent for Next-Generation Sequencing (NGS) to look for genetic mutations?
- 3.What is my tumor's MSI (Microsatellite Instability) status and TMB (Tumor Mutational Burden)?
- 4.Do I have a KRAS mutation, and how does that affect my prognosis?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (8)
- 1
Perihilar Cholangiocarcinoma Originating in Peribiliary Glands: Insights from a Case without Precancerous Lesions.
Shirota Y, Ueda Y, Nakanuma Y, et al.
The American journal of case reports 2024; (25()):e945519 doi:10.12659/AJCR.945519.
PMID: 39680512 - 2
Radial margin status should be determined in resected perihilar cholangiocarcinoma.
de Wilde RF, Groot Koerkamp B
Hepatobiliary surgery and nutrition 2019; (8(5)):557-559 doi:10.21037/hbsn.2019.07.19.
PMID: 31673558 - 3
Survival outcomes of surgical resection in perihilar cholangiocarcinoma in endemic area of O. Viverrini, Northeast Thailand.
Sarkhampee P, Junrungsee S, Tantraworasin A, et al.
Asian journal of surgery 2024; (47(7)):2991-2998 doi:10.1016/j.asjsur.2024.03.116.
PMID: 38519311 - 4
Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study.
Nassour I, Mokdad AA, Porembka MR, et al.
Annals of surgical oncology 2018; (25(5)):1193-1201 doi:10.1245/s10434-018-6388-7.
PMID: 29488187 - 5
Surgical management, including the role of transplantation, for intrahepatic and peri-hilar cholangiocarcinoma.
Malik AK, Davidson BR, Manas DM
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2025; (51(2)):108248 doi:10.1016/j.ejso.2024.108248.
PMID: 38467524 - 6
The Impact of KRAS Mutational Status on Long-Term Survival following Liver Resection for Hilar Cholangiocarcinoma.
Ardito F, Razionale F, Campisi A, et al.
Cancers 2022; (14(18)) doi:10.3390/cancers14184370.
PMID: 36139531 - 7
Pathological Complete Response after Pembrolizumab Treatment for Unresectable Perihilar Cholangiocarcinoma with High Microsatellite Instability: A Case Report.
Inokawa Y, Mizuno H, Yamada M, et al.
Surgical case reports 2025; (11(1)) doi:10.70352/scrj.cr.25-0025.
PMID: 40308703 - 8
Advanced Cholangiocarcinoma With High Tumor Mutation Burden Achieving Complete Response to Immune Check Point Inhibitor.
Okabe H, Masuda T, Nitta H, et al.
Anticancer research 2024; (44(7)):3199-3203 doi:10.21873/anticanres.17135.
PMID: 38925819
This page explains perihilar cholangiocarcinoma (pCCA) pathology and genetics for educational purposes. Always consult your oncologist or pathologist to interpret your specific test results.
Get notified when new evidence is published on Perihilar cholangiocarcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.